慢性乙型肝炎病毒基因型与干扰素治疗应答的关系

姚刚; 章廉; 包立华

慢性乙型肝炎病毒基因型与干扰素治疗应答的关系

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2266
- HTML全文浏览量: 16
- PDF下载量: 771
- 被引次数: 0
出版历程
- 出版日期: 2002-05-20

HBV genotypes and efficacy of interferon-α on patients with chronic hepatitis B.

摘要

摘要: 观察慢性乙型肝炎病毒基因型与α -干扰素治疗慢性乙型肝炎患者疗效的关系。利用限制性片段长度多态性分析技术 ,由限制性内切酶AvaⅡ和DpnⅡ作用于前S区扩增片段建立的简便的HBV基因型分型方法 ,对 6 0例经干扰素治疗的慢性乙型肝炎患者的血清HBV进行基因型测定 ,显示B基因型 31例（5 1 7% ） ,C基因型 2 6（43 3% ） ,D基因型 3例（5 0 % ）。B型、C型与干扰素应答无明显差异（P >0 0 5 ） ,3例D型均有效。由于我国大部分地区HBV基因型以B型和C型为主 ,HBV基因型可能不是预测干扰素疗效的重要因素。D型对干扰素应答率高 ,有待进一步研究。
- 乙型肝炎病毒 /
- 基因型 /
- α-干扰素 /
- 限制性片段长度多态性
Abstract: To observe the relationship between HBV genotypes of chronic hepatitis B and efficacy of interferon-α therapy. A simplified RFLP method was established with AvaⅡ and DpnⅡ at amplified segment of the pre-S of HBV DNA. The method was applied to 60 serum samples from patients with chronic hepatitis B on IFN-α therapy. The genotype B was detected in 51 7% (31/60) . The difference was not significant in responsive rate to IFN-α therapy between genotype B and genotype C ( P >0 05) . Three patients of genotype D are effective on therapy. The Genotypes B and Genoltypes C are prevalent in a majority of area in our country. HBV genotypes might not be an important predictive factor in determining the efficacy of IFN-α therapy. The study indicates Genotype D is higher in responsive rate to IFN-α therapy.
- Hepatits B virus (HBV) /
- Genotypes /
- Interferon-α (IFN-α) /
- Restriction fragment length polymorphism (RFLP)

HTML全文

参考文献(8)

[1]Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparision of surface antigen subtypes[J]. J Gen Virol, 1988, 69∶2575-2583.

[2]Lindh M, Gonzalez JE, Norkrans G, et al. Genotyping of hepatitis B virus by retriction pattern analysis of a pre-S amplicon [J]. J Virol Methods, 1998, 72∶163-174.

[3]Brook MG, Karayiannis P, Thomas H C. Which patients with chronic hepatitis B virus infection will respond to alpola-inteferon therapy? A statistical analysis of predictive factors [J]. Hepatology, 1989, 10∶761-765.

[4] Perrillo R P. Antiviral therapy of chronic hepatitis B: past, present and furture[J]. J Hepatol, 1993, 17 (supple) : S56.7.

[5]Lindh M, Hannoun C, Dhion AP et al. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers [J]. J Infect Dis, 1999, 179∶755.

[6]Fang ZL. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China[J]. J med virol, 1998, 56 (1) ∶18.

[7]Sangfelt P, Norder H, Magnius LO, et al. IFN-2b treatment in HBV carriers, effect on HBV DNA levels in children infected with different genotypes [J]. Acta Pediat, 1997, 86∶135-137.

[8]Zhang X, Zoulin F, Habersetzer F, et al. Analysis of HBV genotypes and pre-core region variability during IFN treatment of HBe antigen negative chronic hepatitis B [J]. J Med Virol, 1996, 48∶8-16.

施引文献

资源附件(0)

访问统计